Clinical development of MVA-based therapeutic cancer vaccines.
about
Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.Experimental vaccines against potentially pandemic and highly pathogenic avian influenza virusesFowlpox virus recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical carcinoma elicit humoral and cell-mediated responses in rabbits.Strategies for cancer vaccine development.A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers.Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.A changing landscape in castration-resistant prostate cancer treatmentTLR2 ligation protects effector T cells from regulatory T-cell mediated suppression and repolarizes T helper responses following MVA-based cancer immunotherapy.Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines.Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses.Strategies used for MUC1 immunotherapy: preclinical studies.Strategies used for MUC1 immunotherapy: human clinical studies.Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 proteinRadiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.Immunotherapy for prostate cancer: an emerging treatment modality.MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.Oncolytic vaccinia virus for the treatment of cancer.Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.The unfolding treatment landscape for men with castration-resistant prostate cancer.Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer.The immunogenicity of the tumor-associated antigen α-fetoprotein is enhanced by a fusion with a transmembrane domain.Vaccine Delivery Methods into the FutureTrial Watch: DNA vaccines for cancer therapy.Q56898607
P2860
Q30375979-99E9322C-221F-46B5-BB17-02BE5FD4E019Q30427591-DBCE1B42-9BD8-4D5A-9934-96C957091CB1Q33863923-22CFADA9-168B-48A3-8751-137FA52C96BDQ34038338-DDAAFB5C-C566-410A-A28D-CAB4E2360425Q35154570-B95A8287-E3F4-4922-A4A3-E2788AA8750FQ35571248-89C07B72-4A51-4F00-9B29-3C2BF43BEBA9Q36101308-90943080-60A8-48E5-9435-1D136F1C2197Q36456469-40445963-56BD-48EE-AF3C-6C48F04D37C1Q36846282-D4FA2355-E028-4D0D-AFA4-73255ED4F73DQ36849770-C54DF75D-0670-4A51-B068-18053218DD4BQ36947039-918EA59B-C34A-4746-A8EA-EE3A3B3636E8Q37259594-086E3FE7-CFB0-4427-9DCC-05D9556BDF0BQ37259597-1AD18DCA-A48E-450E-9E6D-BC7903D64880Q37545001-FD39FEFD-5FE1-407E-A2D9-15DE3D6F5686Q37589407-7333DB7C-2696-45C7-B393-771BE37EB0B6Q37691634-4028DBF0-FDC3-4093-9377-F0E938F409ACQ37737313-09A177F5-72F0-4753-AFE8-62DA07626F41Q37845399-7E047DEE-DF65-4999-B8C9-4F22FCF73252Q37984189-616D045C-4930-40CA-B135-B4E9C5232088Q38056914-4D691661-549D-476E-A050-4DF7140BA335Q40068135-433D7881-1BAD-4757-8953-09264675352FQ41876459-C08993F6-1849-4569-8DB8-342C283B4E65Q42434139-FEC53096-98F0-4AC0-BC2E-15668CF0883AQ42552005-D9F37A08-1D56-4CF0-A537-82D1074D5B6FQ56898607-04E3EA1B-606A-4A8B-9008-4987485A6019
P2860
Clinical development of MVA-based therapeutic cancer vaccines.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical development of MVA-based therapeutic cancer vaccines.
@en
Clinical development of MVA-based therapeutic cancer vaccines.
@nl
type
label
Clinical development of MVA-based therapeutic cancer vaccines.
@en
Clinical development of MVA-based therapeutic cancer vaccines.
@nl
prefLabel
Clinical development of MVA-based therapeutic cancer vaccines.
@en
Clinical development of MVA-based therapeutic cancer vaccines.
@nl
P2860
P356
P1476
Clinical development of MVA-based therapeutic cancer vaccines.
@en
P2093
Bruce Acres
Jean-Yves Bonnefoy
P2860
P304
P356
10.1586/14760584.7.7.889
P577
2008-09-01T00:00:00Z